MAPPING THE EORTC QLQ-C30 ONTO THE EQ-5D-5L UTILITY INDEX IN PATIENTS WITH BREAST CANCER IN SPAIN
Author(s)
Amaia Bilbao, Dr1, Idoia Castillo-Sintes, MSc2, Nerea González-Hernández, Dr3, Maria Jose Legarreta, MSc4, Susana García-Gutiérrez, Dr5, Miren Orive, Dr6, Cristina Sarasqueta, Dr7, Patricia Cobos, Dr8, Josefa Ferreiro, Dr9, Irantzu Barrio, Dr10, María Padilla-Ruiz, Dr11, Máximo Redondo, Dr11, Amador Rivero Javier, Dr12, Lilisbeth Perestelo-Pérez, Dr13, José M Quintana, Dr5.
1Osakidetza, Basurto University Hospital, Research and Innovation Unit. Biosistemak Institute for Health Systems Research. Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Bilbao, Spain, 2Biosistemak Institute for Health Systems Research. Osakidetza, Basurto University Hospital, Research and Innovation Unit. Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Bilbao, Spain, 3Biosistemak Institute for Health Systems Research. Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Bilbao, Spain, 4Biosistemak Institute for Health Systems Research. Osakidetza, Galdakao-Usansolo University Hospital, Research Unit. Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Galdakao, Spain, 5Osakidetza, Galdakao-Usansolo University Hospital, Research Unit. Biosistemak Institute for Health Systems Research. Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Galdakao, Spain, 6Social Psychology Dpt., Faculty of Pharmacy, University of the Basque Country. Osakidetza, Galdakao-Usansolo University Hospital, Research Unit. Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Vitoria, Spain, 7Osakidetza, Donostia University Hospital, Research Unit. Biogipuzkoa Health Research Institute. Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Donostia, Spain, 8Osakidetza, Cruces University Hospital, Human Reproduction Unit, Barakaldo, Spain, 9Osakidetza, Galdakao-Usansolo University Hospital, Oncology Unit, Galadakao, Spain, 10Mathematics Dpt., Faculty of Science and Technology, University of the Basque Country. BCAM Center. Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Leioa, Spain, 11Costa del Sol University Hospital, Research and Innovation Unit. Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Marbella, Spain, 12Canary Islands Foundation for Health Care Research (FUNCANIS). Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Tenerife, Spain, 13Canary Islands Health Service (SESCS), Evaluation Unit. Center for Biomedical Research of the Canary Islands (CIBICAN). Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Tenerife, Spain.
1Osakidetza, Basurto University Hospital, Research and Innovation Unit. Biosistemak Institute for Health Systems Research. Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Bilbao, Spain, 2Biosistemak Institute for Health Systems Research. Osakidetza, Basurto University Hospital, Research and Innovation Unit. Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Bilbao, Spain, 3Biosistemak Institute for Health Systems Research. Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Bilbao, Spain, 4Biosistemak Institute for Health Systems Research. Osakidetza, Galdakao-Usansolo University Hospital, Research Unit. Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Galdakao, Spain, 5Osakidetza, Galdakao-Usansolo University Hospital, Research Unit. Biosistemak Institute for Health Systems Research. Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Galdakao, Spain, 6Social Psychology Dpt., Faculty of Pharmacy, University of the Basque Country. Osakidetza, Galdakao-Usansolo University Hospital, Research Unit. Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Vitoria, Spain, 7Osakidetza, Donostia University Hospital, Research Unit. Biogipuzkoa Health Research Institute. Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Donostia, Spain, 8Osakidetza, Cruces University Hospital, Human Reproduction Unit, Barakaldo, Spain, 9Osakidetza, Galdakao-Usansolo University Hospital, Oncology Unit, Galadakao, Spain, 10Mathematics Dpt., Faculty of Science and Technology, University of the Basque Country. BCAM Center. Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Leioa, Spain, 11Costa del Sol University Hospital, Research and Innovation Unit. Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Marbella, Spain, 12Canary Islands Foundation for Health Care Research (FUNCANIS). Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Tenerife, Spain, 13Canary Islands Health Service (SESCS), Evaluation Unit. Center for Biomedical Research of the Canary Islands (CIBICAN). Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Tenerife, Spain.
OBJECTIVES: Breast cancer (BC) significantly affects patients' quality of life (QoL) and represents a public health and economic burden, making cost-effectiveness analyses essential for healthcare decisions. These analyses depend on quality-adjusted life years (QALYs), calculated using utility indices derived from generic instruments such as the EQ-5D-5L questionnaire. However, oncology practice favors disease-specific measures like the EORTC QLQ-C30 questionnaire, creating a need for statistical mapping methods to translate these disease-specific scores into utility indices. The objective was to develop, compare, and validate statistical mapping algorithms that estimate EQ-5D-5L utility indices from EORTC QLQ-C30 scores in patients with BC, enabling their use in cost-effectiveness analyses.
METHODS: A total of 1323 women with BC from 13 hospitals in Spain were recruited from April 2013 to May 2015. Models were developed using data from women who completed the EORTC-QLQ-C30 and EQ-5D-5L questionnaires (n=1323) and were validated using follow-up questionnaire data collected two years later (n=1105). General linear models (GLMs), Tobit models and Beta regression models were applied.
RESULTS: At baseline, the mean age was 58 years (SD=12.3) and the observed EQ-5D-5L utility index ranged from -0.089 to 1, with a mean of 0.860 (SD=0.165) and 338 patients reporting full health (24.9%). At follow-up, the utility index ranged from -0.44 to 1, with a mean of 0.832 (SD=0.201). Three models performed well and similarly in the derivation (Adj. R2=53%-59%, MAE=0.07-0.08, RMSE=0.10-0.11, ICC=0.72-0.75) and the validation sample (MAE=0.07-0.08, RMSE=0.11-0.12, ICC=0.78-0.82). Although prediction was less accurate for lower utility values, the errors were small for most of the sample and remained within acceptable limits.
CONCLUSIONS: This study provides a set of validated mapping algorithms to estimate EQ-5D-5L utility indices from EORTC QLQ-C30 scores in patients with BC, thereby enabling the incorporation of disease-specific QoL data into cost-effectiveness analyses.
METHODS: A total of 1323 women with BC from 13 hospitals in Spain were recruited from April 2013 to May 2015. Models were developed using data from women who completed the EORTC-QLQ-C30 and EQ-5D-5L questionnaires (n=1323) and were validated using follow-up questionnaire data collected two years later (n=1105). General linear models (GLMs), Tobit models and Beta regression models were applied.
RESULTS: At baseline, the mean age was 58 years (SD=12.3) and the observed EQ-5D-5L utility index ranged from -0.089 to 1, with a mean of 0.860 (SD=0.165) and 338 patients reporting full health (24.9%). At follow-up, the utility index ranged from -0.44 to 1, with a mean of 0.832 (SD=0.201). Three models performed well and similarly in the derivation (Adj. R2=53%-59%, MAE=0.07-0.08, RMSE=0.10-0.11, ICC=0.72-0.75) and the validation sample (MAE=0.07-0.08, RMSE=0.11-0.12, ICC=0.78-0.82). Although prediction was less accurate for lower utility values, the errors were small for most of the sample and remained within acceptable limits.
CONCLUSIONS: This study provides a set of validated mapping algorithms to estimate EQ-5D-5L utility indices from EORTC QLQ-C30 scores in patients with BC, thereby enabling the incorporation of disease-specific QoL data into cost-effectiveness analyses.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
HTA90
Topic
Clinical Outcomes, Health Technology Assessment, Patient-Centered Research
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology